SBIR/STTR Research Award

Nanosphere-Antibiotic Corneal Contact Lens Delivery System

Award identifier c6164774a1dd6191615d26de28ec392f4dab2886660b386c2772ebc677a1962eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$357,146

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VISTA SCIENTIFIC, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Nanosphere technology will be utilized for controlled ophthalmic antibiotic delivery via a hydrogel polymer contact lens device. The device will be useful for a number of conditions including traumatic injury, surface disorders, and post-surgical healing. The advantage of this medicated bandage system over traditional therapy is that a consistent dose of antibiotic (ciprofloxacin) will be delivered over a 7-14 day period while protecting the cornea with a hydrogel banda ge lens. The sustained delivery of ciprofloxacin precludes the use of topical antibiotic drops, resulting in improved patient compliance, convenience, and subsequent efficacy. The bandage effect of the device assists in pain relief and wound healing at the surface of the eye, as is commonly done using current, non-medicated hydrogel bandage contact lenses. The nanosphere technology utilized in this project allows for customized encapsulation to control drug release. These nanospheres are unique in that they are based on a carbohydrate core, and have a hydrophilic shell rendering it compatible with a hydrophilic system such as our hydrogel contact lens material. They are biodegradable, non-toxic, and stable in solution. Both the shell and the core can be func tionalized independently, allowing for modifications and enhancements to further control drug release. The specific aims of this project during year 1 include synthesis of the nanospheres and encapsulation of the antibiotic; polymerization of the nanospher es into the hydrogel material suitable for ocular use; and testing the release characteristics of the antibiotic from the hydrogel lenses. During year 2 of this project, the casting and manufacturing specifics for the lenses will be determined, and the pre -clinical safety and efficacy of the lenses will be tested, according to FDA guidelines. PUBLIC HEALTH RELEVANCE: The product in development will improve patient care by providing a more efficient, convenient, and consistent means of antibiotic drug delive ry to the surface of the eye, while serving as a bandage to decrease intense ocular pain and to aid in ocular surface healing. This product will eliminate the necessity of giving frequent doses of antibiotic drops for a wide range of conditions compromisin g the surface of the eye. Such common conditions include active infections of the cornea and conjunctiva, as well as for prevention of pain or potential infection associated with severe dry eye, trauma, or ocular surgery such as cataract, glaucoma or laser refractive surgery procedures.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.